Francisco José Farias Borges dos Reis

I Latin American Guidelines for the assessment and management of decompensated heart failure

Edimar Alcides Bocchi, Fabio Vilas-Boas, Sergio Perrone, Angel G Caamano, Nadine Clausell, Maria da Consolacao VMoreira, Jorge Thierer, Hugo Omar Grancelli, Carlos Vicente Serrano Junior, Denilson Albuquerque, Dirceu Almeida,Fernando Bacal, Luis Felipe Moreira, Adonay Mendonza, Antonio Magana, Arturo Tejeda, Daniel Chafes, Efraim Gomez,Erick Bogantes, Estela Azeka, Evandro Tinoco Mesquita, Francisco Jose Farias B Reis, Hector Mora, Humberto Vilacorta,Jesus Sanches, Joao David de Souza Neto, Jose Luis Vuksovic, Juan Paes Moreno, Julio Aspe y Rosas, Lidia ZytynskiMoura, Luis Antonio de Almeida Campos, Luis Eduardo Rohde, Marcos Parioma Javier, Martin Garrido Garduno, MucioTavares, Pablo Castro Galvez, Raul Spinoza, Reynaldo Castro de Miranda, Ricardo Mourilhe Rocha, Roberto Paganini,Rodolfo Castano Guerra, Salvador Rassi, Sofia Lagudis, Solange Bordignon, Solon Navarette, Waldo Fernandes, AntonioCarlos Pereira Barretto, Victor Issa, Jorge Ilha Guimaraes.

Clinical Outcomes of Thirteen Patients with Acute Chagas Disease Acquired through Oral Transmission from Two Urban Outbreaks in Northeastern Brazil

Background Outbreaks of orally transmitted Trypanosoma cruzi continue to be reported in Brazil and are associated with a high mortality rate, mainly due to myocarditis. Methods This study is a detailed report on the disease progression of acute Chagas disease in 13 patients who were infected during two micro-outbreaks in two northeastern Brazilian towns. Clinical outcomes as well as EKG and ECHO results are described, both before and after benznidazole treatment. Results Fever and dyspnea were the most frequent symptoms observed. Other clinical findings included myalgia, periorbital edema, headache and systolic murmur. Two patients died of cardiac failure before receiving benznidazole treatment. EKG and ECHO findings frequently showed a disturbance in ventricular repolarization and pericardial effusion. Ventricular dysfunction (ejection fraction <55%) was present in 27.3% of patients. After treatment, EKG readings normalized in 91.7% of patients. Ventricular repolarization abnormalities persisted in 50% of the patients, while sinus bradycardia was observed in 18%. The systolic ejection fraction normalized in two out of three patients with initially depressed ventricular function, while pericardial effusion disappeared. Conclusions Myocarditis is frequently found and potentially severe in patients with acute Chagas disease. Benznidazole treatment may improve clinical symptoms, as well as EKG and ECHO findings.

Chagas Disease Is an Independent Risk Factor for Stroke: Baseline Characteristics of a Chagas Disease Cohort

Background and Purpose— Chagas disease (CD) is frequently associated with cardioembolic stroke in South America. Our objective was to identify the predictors of stroke in a region where CD is endemic. Method— We screened 305 consecutive cardiopathy patients. Significant predictors of stroke in univariable analyses were included in a multivariable model. Results— Stroke was more frequent in CD (15.0%) compared with other cardiopathies (6.3%; P=0.015). Other predictors of stroke in univariable analyses were previous diabetes or cardioversion and use of amiodarone, antiplatelet agents, and warfarin. In multivariable analysis, remaining predictors of stroke were CD (odds ratio [OR], 1.09; 95% CI, 1.02 to 1.17), cardioversion (OR, 1.07; 95% CI, 1.02 to 1.13), and diabetes (OR, 1.12; 95% CI, 1.01 to 1.24). Conclusions— In conclusion, CD is a risk factor for stroke, independent of systolic dysfunction or presence of cardiac arrhythmias.

Aspectos clínicos e terapêuticos da insuficiência cardíaca por doença de Chagas

OBJECTIVE Describe the clinical and therapeutic characteristics of patients with heart failure (HF) secondary to chronic chagasic cardiomyopathy and evaluate if these characteristics are different from those found in other etiologies. METHODS A prospective analysis of the patients treated between August 2003 and June 2004 at a HF referral outpatient clinic was conducted. RESULTS Three hundred and fifty six patients diagnosed with HF were included in the study. Chagasic cardiomyopathy was the most common etiology (48% of the cases). Other etiologies included hypertensive cardiomyopathy in 19% of the patients, idiopathic dilated in 11% and ischemic in 9%. Patients with HF secondary to chagasic cardiomyopathy were more frequently from non-white ethnic groups (88 vs. 75%; p = 0.002), had a family history of Chagas disease (57 vs. 21%; p = 0.001), had the disease for a longer length of time (71 vs. 56 months; p = 0.034), had lower levels of education (4.4 +/- 4.1 vs. 5.7 +/- 4.2 years of study; p = 0.004), had a lower heart rate (69 +/- 12 vs. 73 +/- 13; p = 0.03) and a lower systolic blood pressure (121 +/- 25 vs. 129 +/- 28 mmHg; p = 0.006). There was also a higher incidence of the use of amiodarone (22 vs. 13%; p = 0.036) and artificial pacemakers (15 vs. 1%; p = 0.001). There was a lower usage of beta-blockers (39 vs. 59%; p = 0.001). CONCLUSION In this sample of HF outpatients, in a state with a high prevalence of Chagas disease, chagasic cardiomyopathy was the most common etiology and they presented some unique clinical and therapeutic characteristics in comparison to other heart failure patients.

Cognitive dysfunction in congestive heart failure: transcranial Doppler evidence of microembolic etiology

Cognitive symptoms are common in patients with congestive heart failure (CHF) and are usually attributed to low cerebral blood flow. In the present study, we aimed to evaluate global cognitive function (Mini Mental State Exam MMSE) in relation to both cardiac function (evaluated by echocardiogram) and cerebrovascular hemodynamics (evaluated by transcranial Doppler TCD) in CHF patients. In 83 patients studied, no correlation was found between echocardiographic parameters and MMSE scores. In contrast, a significant correlation was found between right middle cerebral artery (RMCA) mean flow velocity and MMSE score (r=0.231 p=0.039), as well as between RMCA pulsatility index and MMSE score (rs= -0.292 p=0.015). After excluding patients with a previous history of stroke, only RMCA pulsatility index correlated with MMSE score (rs=-0,314 p=0,007). The relationship between high cerebrovascular resistance and worse cognitive scores suggest that microembolism may be responsible for a significant proportion of cognitive symptoms in CHF patients.

Prevalência de dislipidemias em adultos da demanda laboratorial de Salvador, Brasil

PURPOSE To determine the prevalence of dyslipidemia in non-hospital laboratory tests of adults from Salvador, Brazil. METHODS The study was carried out in subjects from a probabilistic sample of 25% of a total of 104 local laboratories that used the same enzymatic method for lipid analysis with the quality control as recommended by the Brazilian Society of Clinical Analyses. These represented 93% of all non-hospital laboratories of Salvador in 1995. The odd months of 1995 were selected for sampling in the present study. Criteria for dyslipidemias were: total cholesterol > or = 240; LDL > or = 160; HDL < 35 and triglycerides > or = 200 mg/dl. Prevalence rates and their 95% confidence intervals (CI) and chi 2 test were used in the analyses. RESULTS Tests from two of the 26 laboratories were not used in the analyses due to file problems or refusal. 7,392 adults were screened, 65% female. We observed prevalence (95% CI) of hypercholesterolemia in 30.0 (27.8; 32.2)%, high LDL in 30.1 (30.8; 35.4)% and hypertriglyceridemia in 30.4 (29.0; 31.4)% of the females. As to the male subjects, prevalences were; 24.0 (20.5; 27.5)% for hypercholesterolemia, 26.1 (22.4; 29.3)% for high LDL, 27.6 (25.7; 29.5)% for hypertriglyceridemia. All gender differences were significant. Low HDL occurred in 15.9 (14.2; 17.8)% of males and in 8.0 (7.1; 8.9)% of females. CONCLUSION Dyslipidemia is an important risk factor observed in non-hospital laboratory tests of men and women in Salvador. Our data may provide physicians and other health care professionals with objective information to encourage life-style changes.PURPOSE: To determine the prevalence of dyslipidemia in non-hospital laboratory tests of adults from Salvador, Brazil. METHODS: The study was carried out in subjects from a probabilistic sample of 25% of a total of 104 local laboratories that used the same enzymatic method for lipid analysis with the quality control as recommended by the Brazilian Society of Clinical Analyses. These represented 93% of all non-hospital laboratories of Salvador in 1995. The odd months of 1995 were selected for sampling in the present study. Criteria for dyslipidemias were: total cholesterol ³240; LDL ³160; HDL <35 and triglycerides ³200mg/dl. Prevalence rates and their 95% confidence intervals (CI) and c2 test were used in the analyses. RESULTS: Tests from two of the 26 laboratories were not used in the analyses due to file problems or refusal. 7,392 adults were screened, 65% female. We observed prevalence (95% CI) of hypercholesterolemia in 30.0 (27.8; 32.2)%, high LDL in 30.1 (30.8; 35.4)% and hypertriglyceridemia in 30.4 (29.0; 31.4)% of the females. As to the male subjects, prevalences were: 24.0 (20.5; 27.5)% for hypercholesterolemia, 26.1 (22.4; 29.3)% for high LDL, 27.6 (25.7; 29.5)% for hypertriglyceridemia. All gender differences were significant. Low HDL occurred in 15.9 (14.2; 17.8)% of males and in 8.0 (7.1; 8.9)% of females. CONCLUSION: Dyslipidemia is an important risk factor observed in non-hospital laboratory tests of men and women in Salvador. Our data may provide physicians and other health care professionals with objective information to encourage life-style changes.

Sildenafil improves quality of life in men with heart failure and erectile dysfunction

Patients with congestive heart failure (CHF) have specific factors that enhance the risk for erectile dysfunction (ED), such as low cardiac output and the use of drugs with vasodilator effect. ED can negatively affect interpersonal relationships and self-esteem, with significant impact on the quality of life. We hypothesized that the improvement of the sexual dysfunction would enhance the quality of life of individuals with systolic heart failure. This is a prospective study of 12 male CHF patients using a fixed dose of sildenafil during 1 month. Patients were included if they had left ventricular ejection fraction lower than 40% documented by echocardiography and International Index of Erectile Function (IIEF) score lower than 21. The effect of sildenafil in quality of life was evaluated by the Minnesota questionnaire. Improvement in ED was assessed using the IIEF. The mean IIEF5 score was 9.6 (±3.8) before the use of sildenafil and 19.3 (±4.3) after sildenafil (P=0.0001). The mean Minnesota score was 28.75 (±21) before treatment and 12.75 (±10.1) after the intervention (P=0.012). In conclusion, the sexual function improvement provided by sildenafil enhances quality of life in individuals with systolic heart failure.

Suporte ventilatório na capacidade funcional de pacientes com insuficiência cardíaca: estudo piloto

BACKGROUND Heart failure (HF) is an important public health problem, of which main clinical symptoms are dyspnea and fatigue. Noninvasive ventilatory support has been used as adjuvant therapy in cardiac rehabilitation in order to improve the functional capacity of patients. OBJECTIVE To evaluate the functional capacity of patients with HF submitted to ventilatory support. METHODS We evaluated the sociodemographic information, as well as data on quality of life, blood pressure (BP), peripheral oxygen saturation (SpO2), dyspnea, lactate concentration before and after the 6-minute walk test (6MWT) and the distance walked by patients of both sexes with chronic heart failure (CHF), with left ventricular ejection fraction (LVEF) < 45.0% , randomized in two groups: control and CPAP (the group used CPAP - 10 cmH2O for 30 minutes). RESULTS A total of 12 patients, of which 8 were males, with CHF functional class II and III (NYHA) participated in the study. The patients had mean LVEF of 35.3 ± 8.7 and mean age was 46.3 ± 10.3 years. When comparing the control group with the CPAP group at the end of the 6th minute, there was a significant difference between the groups regarding SpO2 values ( CONTROL 93.6 ± 1.5 % vs CPAP: 96.1±1.8%; p = 0.027), index of dyspnea ( CONTROL 13.1 ± 1.16 vs CPAP: 11 ± 0.8; p = 0.009), lactate concentration ( CONTROL 3.3 ± 0.7 mmol/l vs CPAP: 2.3 ± 0.5 mmol/l; p = 0.025) and distance walked at the 6MWT (CONTROL: 420.6 ± 73.8 m vs CPAP: 534 ± 89.91 m; p = 0.038). CONCLUSION The previous use of the CPAP had beneficial effects on SpO2, index of dyspnea, lactate concentration, double product and the distance walked at the 6MWT in patients with CHF when performing the 6MWT.FUNDAMENTO: A insuficiencia cardiaca e um importante problema de saude publica, apresentando a dispneia e a fadiga como principais sintomas clinicos. A utilizacao do suporte ventilatorio nao invasivo vem atuando como coadjuvante da reabilitacao cardiaca na tentativa de melhorar a capacidade funcional dos pacientes. OBJETIVO: Avaliar a capacidade funcional de pacientes com insuficiencia cardiaca submetidos ao suporte ventilatorio. METODOS: Foram avaliados dados sociodemograficos, qualidade de vida, FC, pressao arterial (PA), saturacao periferica de oxigenio (SpO2), dispneia, concentracao de lactato, antes e depois do teste de caminhada de 6 minutos, e a distância percorrida de pacientes com insuficiencia cardiaca cronica (ICC), de ambos os sexos, com fracao FEVE < 45,0%, randomizados em dois grupos: controle e CPAP (utilizou CPAP 10 cmH2O por 30 minutos). RESULTADOS: Participaram 12 pacientes com ICC classe funcional II e III (NYHA), com media de fracao de ejecao do ventriculo esquerdo (FEVE, %) de 35,3 ± 8,7, sendo que 8 eram do sexo masculino. A media de idade foi de 46,3 ± 10,3 anos. Na comparacao entre os grupos Controle e CPAP, no final do 6o min, foi encontrada diferenca significativa nos valores de SpO2% entre os grupos (Controle: 93,6 ± 1,5 % vs CPAP: 96,1 ± 1,8%; p = 0,027), dispneia (Controle: 13,1 ± 1,16 vs CPAP: 11 ± 0,8; p = 0,009), concentracao de lactato (Controle: 3,3 ± 0,7 mmol/l vs CPAP: 2,3 ± 0,5 mmol/l; p = 0,025), e distância percorrida no TC6 (Controle: 420,6 ± 73,8 m vs CPAP: 534 ± 89,91 m; p = 0,038). CONCLUSAO: A realizacao previa do CPAP apresentou efeitos beneficos na SpO2, na dispneia, na concentracao de lactato, no duplo produto e na distância percorrida no TC6 de pacientes com ICC na realizacao do TC6.

Stroke History and Chagas Disease Are Independent Predictors of Silent Cerebral Microembolism in Patients with Congestive Heart Failure

Background: Chagas disease is endemic in South and Central America, where 18 million individuals are infected by Trypanosoma cruzi, causing congestive heart failure (CHF) and cardioembolic stroke. Transcranial Doppler (TCD) is able to detect real-time microembolic signals (MES) to the brain vessels and may represent a surrogate marker of stroke risk. We aimed to determine predictors of MES in a population of patients with CHF. Methods: Consecutive CHF patients from a university-based cardiomyopathy clinic underwent TCD recording of the middle cerebral artery for 60 min by a single investigator who was blinded to all clinical data including cardiomyopathy etiology. Predictors of MES were sought by multivariable logistic regression analysis. Results: From April 2004 to February 2009, 144 patients were studied, including 62 (44.6%) patients with Chagas disease. MES were detected in 9 (6.2%) patients and were more frequent in patients with Chagas disease than in patients with other causes of CHF (12.9 vs. 1.2%, p = 0.005). In multivariate analysis corrected for age and left-ventricular ejection fraction, predictors of MES were Chagas disease (odds ratio = 1.15, 95% confidence interval = 1.05–1.26, p = 0.004) and stroke history (odds ratio = 1.27, 95% confidence interval = 1.08–1.50, p = 0.005). Conclusions: Chagas disease and stroke history are risk factors for MES independent of cardiac disease severity. Other mechanisms besides structural cardiac disease may be operative, increasing embolic risk in Chagas disease.

Prevalence and prognostic value of ventricular dyssynchrony in chagas cardiomyopathy

BACKGROUND: Chagas cardiomyopathy is one important cause of heart failure in Latin America. Ventricular dyssynchrony may be a factor of decompensation in the course of this disease, but there are no data on its prevalence and its main prognostic implications yet. OBJECTIVE: Describe prevalence and prognostic value of ventricular dyssynchrony in Chagas cardiomyopathy. METHODS: 56 patients with Chagas cardiomyopathy were consecutively selected by two positive serologies and an ejection fraction 0.12 s (85% and 89%, respectively, p = 0.66). Twenty events were recorded. The incidence of combined events was similar in patients with or without intraventricular dyssynchrony (35% versus 38%, p = 0.9) and those with or without interventricular dyssynchrony (39% versus 34%, p = 0.73). CONCLUSION: Patients with Chagas cardiomyopathy have high intraventricular and moderate interventricular prevalence of dyssynchrony. The high prevalence is independent from the QRS width. The ventricular dyssynchrony does not have any prognostic value in patients with Chagas cardiomyopathy.BACKGROUND Chagas cardiomyopathy is one important cause of heart failure in Latin America. Ventricular dyssynchrony may be a factor of decompensation in the course of this disease, but there are no data on its prevalence and its main prognostic implications yet. OBJECTIVE Describe prevalence and prognostic value of ventricular dyssynchrony in Chagas cardiomyopathy. METHODS 56 patients with Chagas cardiomyopathy were consecutively selected by two positive serologies and an ejection fraction < 45% in the echocardiogram. The echocardiogram evaluated the presence of intraventricular dyssynchrony using 3 criteria and interventricular dyssynchrony using 1 criterion. Patients were followed for 21 ± 14 months and cardiac events were defined as the combination of death and hospitalization. RESULTS The average age of the population was 56 ± 10 years, 50% males. Mean ejection fraction was 30 ± 8% and 87% presented functional class I/II (NYHA). The prevalence of interventricular dyssynchrony was 34% (95% CI: 22%-48%) and intraventricular dyssynchrony had a prevalence of 85% (95% CI: 75%-93%). The prevalence of intraventricular dyssynchrony was similar among patients with QRS duration < 0.12 s or > 0.12 s (85% and 89%, respectively, p = 0.66). Twenty events were recorded. The incidence of combined events was similar in patients with or without intraventricular dyssynchrony (35% versus 38%, p = 0.9) and those with or without interventricular dyssynchrony (39% versus 34%, p = 0.73). CONCLUSION Patients with Chagas cardiomyopathy have high intraventricular and moderate interventricular prevalence of dyssynchrony. The high prevalence is independent from the QRS width. The ventricular dyssynchrony does not have any prognostic value in patients with Chagas cardiomyopathy.